Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 5, 2015, Pages 539-542

  Shawcross, Debbie L ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

ammonia; cirrhosis; gut dysbiosis; hepatic encephalopathy; immune dysfunction; inflammation; microbiota

Indexed keywords

AMMONIA; INTERLEUKIN 10; INTERLEUKIN 8; RIFAXIMIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; CYTOKINE PRODUCTION; DETOXIFICATION; DYSBIOSIS; ENDOTOXEMIA; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; LIVER CIRRHOSIS; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SURVIVAL TIME; COMPLICATION; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; MICROBIOLOGY;

DYSBIOSIS; HEPATIC ENCEPHALOPATHY; HUMANS; IMMUNE SYSTEM DISEASES;

EID: 84928580431     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1035257     Document Type: Review

References (29)

1. Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51(5): 1675-82
2. Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011; 106(9): 1646-53
3. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the european association for the study of the liver. Hepatology 2014; 60(2): 715-35
4. Shawcross DL, Olde Damink SW, Butterworth -RF, et al. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005; 20(3): 169-79
5. Bernal W, Hall C, Karvellas C, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007; 46(6): 1844-52
6. Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM 2006; 8(6): 433-5
7. Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011; 54(4): 640-9
8. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005; 38(8): 696-9
9. Shawcross D, Davies N, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40(2): 247-54
10. Jalan R, Olde Damink SW, Hayes PC, et al. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol 2004; 41(4): 613-20
11. Wright G, Davies N, Shawcross D, et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007; 45(6): 1517-26
12. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34(1): 32-7
13. Singh R, Bullard J, Kalra M, et al. Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin Immunol 2011; 138(1): 41-9
14. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60(5): 940-7
15. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513(7516): 59-64
16. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8(4): e60042
17. Berry PA, Antoniades CG, Carey I, et al. Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med 2011; 37(3): 453-60
18. Taylor NJ, Manakkat Vijay GK, Abeles RD, et al. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther 2014; 40(6): 705-15
19. Shawcross D, Wright G, Stadlbauer V, et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008; 48(4): 1202-12
20. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005; 365(9457): 431-3
21. Prasad S, Dhimna R, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59
22. Als-Nielsen B, Gluud L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. Br Med J 2004; 328: 1046-50
23. Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014; 59(3): 1073-83
24. Bai M, He C, Yin Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther 2014; 40(1): 63-71
25. Kristiansen RG, Rose CF, Fuskevag OM, et al. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway. Am J Physiol Gastrointest Liver Physiol 2014; 307(10): G1024-31
26. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39(5): 1441-9
27. Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014; 39(10): 1113-25
28. Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014; 147(6): 1327-37
29. Stadlbauer V, Mookerjee R, Hodges S et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48(6): 945-51